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Evaluation and screening of vaccines against tuberculosis 
depends on development of proper cost effective disease 
models along with identification of different immune markers 
that can be used as surrogate endpoints of protection in pre-
clinical and clinical studies. The objective of the present 
study was therefore evaluation of subcutaneous model of 
M.tuberculosis infection along with investigation of different 
immune biomarkers of tuberculosis infection in BALB/c 
mice. Groups of mice were infected subcutaneously with two 
different doses : high (2×106 CFU) and low doses (2×102 
CFU) of M.tuberculosis and immune markers including hu-
moral and cellular markers were evaluated 30 days post 
M.tuberculosis infections. Based on results, we found that 
high dose of subcutaneous infection produced chronic dis-
ease with significant (p<0.001) production of immune mark-
ers of infection like IFNγ, heat shock antigens (65, 71) and 
antibody titres against panel of M.tuberculosis antigens 
(ESAT-6, CFP-10, Ag85B, 45kDa, GroES, Hsp-16) all of 
which correlated with high bacterial burden in lungs and 
spleen. To conclude high dose of subcutaneous infection pro-
duces chronic TB infection in mice and can be used as con-
venient alternative to aerosol models in resource limited 
settings. Moreover assessment of immune markers namely 
mycobacterial antigens and antibodies can provide us val-
uable insights on modulation of immune response post 
infection. However further investigations along with opti-
mization of study protocols are needed to justify the outcome 
of present study and establish such markers as surrogate 
endpoints of vaccine protection in preclinical and clinical 
studies in future.
[Immune Network 2015;15(2):83-90]
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INTRODUCTION
Bacillus Calmette Guerin (BCG), only licensed Tuberculosis 
(TB) vaccine, has afforded limited protection against TB de-
spite of its widespread use in developing countries like India 
(1,2). To overcome this limitation, a number of different vac-
cination strategies have been investigated using different ani-
mal models of TB infection (3,4). However, animal models 
that strictly reproduce the human host-M.tuberculosis (MTB) 
relationship are required to evaluate new vaccines and thera-
pies (5). Aerosol model by far is most widely used route to 
establish TB infection in mouse since it replicates immuno-
logical events in human leading to slow progressive disease 
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development. However, requirement of Biosafety level-3 
(BSL-3) facilities and high maintenance cost limits their usage 
in many resource limited settings of developing world. Other 
routes of infection such as subcutaneous, intravenous and in-
tranasal have been investigated in other studies for develop-
ment of TB model in animals (6-8). Although subcutaneous 
route may not mimic actual development of infection in ani-
mals, however, it can be used as convenient alternative to 
aerosol route (9,10) in resource limited settings. Dose of MTB 
infection used is another contributing factor, since outcome 
of successful infection generally depends on amount of bac-
teria colonizing in lungs and other organs of host animal used 
(11). Thus along with route of infection, standardization of 
optimal dose required for infection is mandatory in develop-
ment of proper disease model of TB infection.
  Another major aspect of vaccine evaluation is identifcation 
of appropriate markers that can be used as surrogate end-
points of protection. Infection with MTB leads to diverse im-
mune response, thereby producing wide range of biomarkers 
(11). Whether or not infection will lead to development of 
disease depends on the outcome of a complex interaction be-
tween the pathogen and the host's immune response (12). 
Therefore, based on our understanding of the pathogen-host 
interactions, the design of superior vaccines or drugs against 
mycobacterial infections can be facilitated. Assesment of bio-
markers, especially MTB antigens and antibodies produced 
during infection provide us useful insight with respect to de-
velopment of disease and may also increase our under-
standing about their production during infection. Moreover, 
with increase in ethical concerns regarding number of ex-
perimental animals used and sacrificed in vaccination studies, 
identification and evaluation of such biomarkers as surrogate end-
points are need in preclinical evaluation of such studies in future.
  Keeping the existing questions in mind, the objective of the 
study was to evaluate subcutaneous model of TB using two 
different doses of MTB infection in BALB/c mice. Apart from 
evaluation of subcutaneous model, the study also focused on 
evaluation of different immune markers post MTB infection 
which can be used as surrogate endpoints for evaluation of 
different vaccine candidates under preclinical and clinical 
stage of development.
MATERIALS AND METHODS
Mice 
Female BALB/c mice, 6∼8 weeks old, were obtained from 
National Institute of Nutrition (NIN, India), Hyderabad. Mice 
were housed under aseptic conditions and provided with 
food and sterile water. Prior to experiments, all mice were 
acclimatized for 15∼20 days.
Antigens and antibodies
MTB H37Rv antigens Ag85B, ESAT-6, CFP-10, Gro-ES, and 
Hsp16 along with Monoclonal antibodies against Hsp16 
(alpha-crystalline like-Rv2031c, hspX), Hsp65 (Rv0440, cpn60.2, 
GroEL) and Hsp71 (Rv0350, DnaK), were obtained from 
Colorado State University, USA under the TB research materi-
als and vaccine testing contract (NO1-AI-75320). The secon-
dary antibody rabbit anti-mouse IgG-HRP was obtained from 
Genei, Banglore, India. MTB purified protein derivative 
(PPD) was obtained from Span Diagnostics, Banglore, India.
MTB infection of mice
The MTB H37Rv was grown in 7H9 Middlebrook Broth 
(Himedia laboratories, India) to mid log phase. The bacterial 
suspension was diluted in phosphate buffered saline (PBS) 
and adjusted according to the number 1 McFarland scale. 
Depending upon the load of mycobacteria to be infected, the 
cultures were serially diluted in sterile saline. Mice were div-
ided into two different experimental groups (n=10, each 
group), and infected subcutaneously with 2×106 CFU (for 
high dose), and 2×102 (low dose). All procedures of cultur-
ing and infection were carried out in BSL facilities. A control 
group of mice (n=10) were separately maintained and sham 
immunized with sterile saline. 30 days after MTB infection, 
blood was collected to obtain serum and used for immuno-
logical marker analysis.
Analysis of Antigen and Antibody response 
MTB heat shock proteins (Hsps) 16, 65, 71 were detected us-
ing in house developed ELISA method as described elsewhere 
(13). Total IgG was estimated using ELISA protocol as de-
scribed earlier by Husain et al. (2). The antibody response 
against MTB antigens (Ag85, ESAT-6, CFP-10, Gro-ES, and 
Hsp16) were evaluated using in house ELISA method devel-
oped by Kashyap et al. Briefly, the 96-well microtiter plates 
(MaxisorpImmunoplate, Nalge Nunc International, Naperville, 
IL, USA) were coated with MTB antigens. After 3 hours of 
incubation at 37oC, the plates were washed and blocked with 
0.25% bovine serum albumin (BSA) in PBS pH 7.4. After 2 
hours of incubation plates were washed twice and kept over-
night at 4oC. Next day plates were incubated with serum sam-
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ples (1:400 diluted) in PBS. After 30 minutes of incubation 
plates were washed and incubated with rabbit anti-mouse 
IgG, HRP conjugate (1:10,000) for 30 min. For colour devel-
opment tetramethyl benzidine in hydrogen peroxide 
(TMB/H2O2) substrate was added and incubated for 10 min. 
The reaction was terminated by adding 2.5 N sulphuric acid 
and the absorbance of colour in each well was read at 450 
nm. Anti-PPD titre was estimated by protocol for antibody de-
tection described earlier.
Enumeration of bacterial load in lungs and spleen 
Thirty days after MTB infection, mice from respective groups 
(n=7) were sacrificed. Lungs and spleen were isolated, homo-
genized and serially diluted. These serially diluted homoge-
nates were innoculated in Middle brook 7H9 liquid medium 
along with oleic acid, albumin, dextrose and catalase (OADC) 
enrichment and antibiotic supplements in BacT culture bottles 
(Biomeriux, France) and were incubated at 37oC in BacT/Alert 
system (Biomerieux) for 28∼35 days. Mycobacterial load in 
organs was determined in terms of mean time taken by organ 
cultures from respective groups to become positive in BacT/Alert 
system as described elsewhere by Kolibab et al. (14).
Cytokine estimation 
Cytokine Interferon gamma (IFN-γ) was assessed in spleeno-
cytes as per manufacturer's instruction (Bender Med System, 
Austria). In brief, anti-IFN-γ-monoclonal coating antibody 
was adsorbed onto micro wells. After two hours of incubation 
at room temperature, the wells were washed and blocked 
with 0.5% BSA in PBS. After one hour, spleenocytes (1:400 
diluted) followed by biotin-conjugated anti-cytokine antibody 
was added to the coated wells. After another two hours of 
incubation, streptavidin-HRP (horseradish peroxidase) was 
added to the wells. After one hour of incubation, substrate 
solution reactive with HRP was added to the wells. The re-
action was terminated by the addition of 2.5 N sulphuric acid 
and the absorbance of colour was read at 450 nm.
Observation of granulomas and necrosis in lung
A section was prepared from the base of the apical lobe and 
from the diaphragmatic lobe of the left lung, representing two 
distinct regions of the organ. Duplicate sections were stained 
with haematoxylin and eosin and Van Gieson in order to aid 
visualization of fibrous tissue. The two sections were scored 
in a blinded fashion for the following features: percentage of 
the section occupied by granulomatous inflammation, healthy 
lung, interstitial pneumonitis, and necrosis. The presence of 
epithelioid cells and the extent of fibrosis and lymphocytic 
infiltration (and whether around vessels or in granulomas in 
both cases) were also assessed. Amount of granulomatous le-
sions were scored in terms of percentage (%) occupied by 
them in lungs.
Ethical Committee Approval
All protocols for animal experiments were approved by 
Institutional Animal Ethics Committee of Central India Institute 
of Medical Sciences, Nagpur.
Statistical analysis
Data are expressed as mean±standard deviation (SD). Graphs 
were plotted using Graph Pad Prism 6 software. For multiple 
comparisons Paired t-test was used for obtaining statistical sig-
nificance in different dose groups. p＜0.05 was considered 
statistically significant (**) and p＜0.001 for highly significant 
(***) values.
RESULTS
High dose of MTB infection induced significant antibody 
response compared to low dose and control mice 
groups
Antibodies were estimated 30 days post MTB infection. Blood 
was harvested from different groups of mice to obtain serum. 
Fig. 1A and B indicates total IgG and anti-PPD titres in differ-
ent dose and control groups. Mice infected with high dose 
showed significantly (p＜0.001) high total IgG and anti-PPD 
response comapred to low dose and control group. Antibody 
titres against panel of MTB H37Rv antigens (ESAT-6, CFP-10, 
GroES, Hsp-16, 45kD, Ag85B) showed similar results with sig-
nificantly higher titres against Ag85B, ESAT-6, and CFP-10 in 
high dose group (Fig. 2). On the contrary, levels of anti-
bodies against GroES, 45kDa and Hsp16 were found to be 
similar in both dose groups. 
Mice infected with high dose showed significant 
levels of MTB Hsp 65 and 71 levels
MTB Hsp (s) were analyzed in mice samples to determine 
course of antigen response in different groups of mice post 
infection. Fig. 3 shows mean (a) Hsp 16 (b) Hsp 65 and (c) 
Hsp71 antigen response in different dose and control group. 
Mice infected with high dose of MTB showed robust Hsp 65 
and 71 levels significant (p＜0.001) compared to low dose 
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Figure 1. (A) Mean Total IgG and 
(B) anti-PPD levels in serum of mice 
(n=7, each group) in high dose, 
low dose and control groups. Anti-
body levels were estimated 30 days 
after development of TB infection. 
Paired t-test was used to compare 
and obtain statistical significance. 
Error bars indicate standard error 
of mean. **Represents significant 
(p＜0.05) and ***represents highly 
significant (p＜0.001) values.
Figure 2. Scatter plot of antibody levels against panel of MTB H37Rv antigens (a) Ag85B (b) 45kDa (c) Hsp 16 (d) GroEs (e) ESAT-6 and (f) 
CFP-10 in serum of mice (n=7, each group) after TB infection. Paired t-test was used to compare and obtain statistical significance. Error bars 
indicate standard error of mean. **Represent significant (p＜0.05) and ***represents highly significant (p＜0.001) values.
groups, while both dose groups showed similar levels of Hsp 
16 post TB infection.
High dose of MTB infection produced higher 
bacterial burden in lungs and spleens of mice 
compared to low dose group
Mice from respective groups (n=7) were sacrificed after 30 
days of MTB infection and mycobacterial load was de-
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Figure 3. Mean mycobacterial Hsp levels (a) mHsp 16 (b) mHsp-65 and (c) mHsp-71 in serum of mice (n=7, each groups) in different dose 
groups. Error bars indicate standard error of mean. **Represents significant (p＜ 0.05) and ***represents highly significant (p＜0.001) values.
Figure 4. Shows mean growth time of MTB in lung and spleen 
homogenates of mice (n=7) collected 30 post MTB infection in different 
dose group. Mice from respective groups were sacrificed and myco-
bacterial load was determined by inoculating serially diluted lung 
homogenates in Middle brook 7H9 liquid medium and incubating at 
37oC in BacT/Alert system (Biomerieux) for 30 days. Bars represent 
mean time required for growth in BacT was taken as a correlate of 
load in respective organs of mice group. Data are shown as ±SD.
**Represent significant (p＜0.05) values.
termined by inoculating serially diluted lung and spleen ho-
mogenates in Middle brook 7H9 liquid medium along with 
OADC enrichment and antibiotic supplements in BAC/T cul-
ture bottles (Biomeriux) and incubated at 37oC in BacT/Alert 
system (Biomerieux) for 28 days. Mean time required for 
growth in BacT was taken as a correlate of mycobacterial 
load in respective organs of mice group. High dose group 
showed comparatively higher bacterial burden in lungs and 
spleen which was significant (p＜0.001) compared to low 
dose group and control group (Fig. 4). Mean positive time 
for high dose group in lungs and spleen was around 
18.5±2.0, 19±0.2 day's compared to 28±1.5, 32±0.5 days 
taken by low dose group. No bacterial burden was observed 
in sham infected control group.
Chronic lung pathology and high IFN-γ response in 
lungs of mice infected with high dose of MTB
Fig. 5A shows photomicrograph of histopathological exami-
nation of lung tissue of mice infected with different dose 
groups. Thirty days after MTB infection, mice from respective 
groups were sacrificed and organs (lungs and spleen) were 
isolated. Tissues were fixed in 10% formalin, paraffin sec-
tioned and stained with Hematoxylin and Eosin. Mice in-
fected with high dose of MTB infection induced chronic lung 
pathology with around 70% lession compared to 40% ob-
served in low dose group. In terms of infiltration, we ob-
served similar results with high infiltration rate in lungs of 
mice infected with high dose (p＜0.001) compared to low 
dose group (Fig. 5B). For interferon analysis, isolated spleen 
cells were homogenized and stimulated with PPD. High dose 
group showed significantly higher levels of IFN-γ (p＜0.001) 
post infection compared to low dose group and control (Fig. 
5C) These levels correlated well with chronic lung pathology 
and higher bacterial burden in lungs of mice thereby indicat-
ing severity of infection.
DISCUSSION
Designing and screening of better vaccine candidates de-
pends on development of proper diseased models of in-
fection (15). Aerosols models by far have been used as gold 
standard for development of TB infection in mice and are 
used for over a decade. Although aerosol route of infection 
is undoubtedly best route in terms of mimicking the actual 
mechanism of infection, it generally requires elaborate labo-
ratory facilities and therefore cannot be used in resource lim-
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Figure 5. (A) Representative Histo-
pathology of lungs section of mice 
(high dose, low dose and control) 
stained with hematoxylin and Eosin. 
(B) along with percentage lympho-
cytic infiltarion in different dose 
groups and control. Mice were sa-
crificed 30 days after MTB infection. 
Arrows indicate percentage of lesions 
covered in lungs. (C) Shows mean 
INF-γ levels in lung homogenates 
of mice at different dose groups. 
Errors bars indicate standard error of 
mean. **Represent significant (p＜
0.05) and ***represents highly sig-
nificant (p＜0.001) values. 
ited settings. Thus, alternate models to aerosol routes need 
to be investigated for laboratories aiming to evaluate vaccine 
efficacy of new molecules under evaluation. Subcutaneous 
and intravenous routes were popular for infecting the animals 
prior to discovery of aerosol inhalation chamber (11). The 
limitation associated with former procedures is the amount of 
dose required for the infection. Since, the amount injected 
and amount reaching the organ may vary due to various im-
munological barriers of host immune system.
  In the present study, we therfore investigated subcutaneous 
model for development of TB using two different doses of 
MTB infection in mice. Rationale for selection of different 
doses was to optimize best dose for development of MTB in-
fection in mice. Groups of mice were challenged subcuta-
neously with high and low dose of MTB. Various correlates 
of antimycobacterial immunity were studied in both dose 
groups at five weeks post MTB infection. Based on the re-
sults, we found that mice infected with high dose of subcuta-
neous infection developed chronic disease with robust IFN-γ 
levels in splenocytes and high titers of MTB antigens and anti-
bodies in serum as compared to low dose group. Histopatho-
logical investigations revealed chronic lung pathology in high 
dose group with around 70% lesion and high lymphocytic in-
filtration rate which correlated well with high load of bacterial 
burden in lungs. On the other hand, low dose group show 
moderate level of infection and comparably low levels of cy-
tokine, organ bacterial load and anti mycobacterial antibodies.
  The present study thus provides some useful insights in 
terms of evaluating efficacy of subcutaneous route and assess-
ment of role of multiple immune markers post MTB infection. 
From the obtained results, it becomes evident that antigen 
and antibodies plays a pleomorphic role in TB infection com-
parable to already established T cell response. Various anti-
gens and antibodies produced during disease states have long 
been used for diagnosis of TB infection in humans (1). MTB 
H37Rv antigens like Ag85B, ESAT-6, CFP-10, and Hsp-16 are 
regarded as major immunodominant antigens produced after 
establishment of TB infection (16). Although cytokines such 
as IFN-γ are key mediators of immunity after infection, dur-
ing the past few years, there are lots of published reports 
which suggest a key role of humoral response in TB 
immunology. In recent studies, it has been shown that anti-
body responses are essential to contain mycobacterial in-
fection, and there is a synergy and mutual interdependence 
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between cell mediated and humoral immunity (17). Zuniga 
et al., in their review article have discussed briefly about dif-
ferent cellular and humoral mechanisms evolved in control 
of TB infection and also suggested a possible role of B cells 
in modulating immune response in TB (18). Report by 
Kozakiewicz et al. suggests B cell plays a vital role in shaping 
immune response against MTB infection (19). Our results thus 
are in agreement with reported evidences supporting the role 
of antibodies and antigens in immune response after TB 
infection. Assessment of multiple biomarkers including mark-
ers of humoral immunity may thus provide valuable evidence 
regarding development of TB infection and can be used as 
surrogate end points for screening of vaccine efficacy in vari-
ous candidate molecules.
  Another major observation of the study is the correlation 
of all the TB markers with lung pathology and MTB load in 
organs of the mice. Each year, large number of animals are 
utilized for studying and evaluating vaccines for TB and other 
infectious diseases. Although there is no exact figure, it is es-
timated that vaccine research, development, production, and 
quality control constitutes around 15% of the total number of 
animals used in biomedical research (20). These animals are 
used at various stages including screening to adjuvant se-
lection, immunogenicity & safety studies, tests for route & 
dose of administration along with formulation etc. Also large 
number of animals are sacrifice in order to study bacterial 
burden in organ and for histopathological procedures. Thus 
evaluation of markers that can be used as an alternatives to 
such procedures are needed to minimize the number of ani-
mal sacrifice thereby reducing ethical constrains on use of an-
imal for vaccination studies. In the present study, we esti-
mated biomarkers of humoral and cellular immunity and 
found that high titres of such biomarkers significantly corre-
lated with bacterial load and lung pathology. Our results 
thereby support our mentioned hypothesis suggesting that 
evaluated markers can be used as alternative to CFU studies 
and histopathological procedures) especially in screening and 
standardization assays in mice model. However these are just 
preliminary observations, and require extensive further inves-
tigation in different animal models using same route of infection.
  There are few limitations associated with study. Major limi-
tation was our inability to use other routes of infection such 
as Intravenous for comparison of disease development and 
biomarker outcome with subcutaneous route. Another limi-
tation was lack of evaluation of markers at different time 
points after MTB infection.
  To conclude, high dose of subcutaneous infection produces 
chronic TB infection in mice and can be use as convenient 
alternative to aerosol models in resource limited settings. 
Moreover, assessment of immune markers such as MTB anti-
gens and antibodies post MTB infection provides valuable in-
sights on modulation of immune response post infection. 
However further investigations along with optimization of 
study protocols are needed to justify the present study out-
come and establish such markers as surrogate endpoints of 
vaccine protection in preclinical and clinical studies in future.
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